Tiger Brokers

BUZZ-Theravance falls as co weighs options including possible sale after drug trial failure

Reuters
Yesterday
BUZZ-Theravance falls as co weighs options including possible sale after drug trial failure

** Shares of  drugmaker Theravance Biopharma TBPH.O fall 31% to $13.51 premarket

** Co says its board is reviewing options, including possible sale, after it ended development of experimental treatment for neurogenic orthostatic hypotension

** Neurogenic orthostatic hypotension is a condition where blood pressure drops sharply when standing

**  Co says it will end development of ampreloxetine and cut operating costs by about 60%, including reducing its administrative staff

**  TBPH says restructuring will affect around half its workforce and save about $70 mln annually

**  Co says it ended 2025 with $326.5 mln in cash; expects ~$400 mln by end-Q1 2026

** Shares up ~99% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10